ASH 2022 | Fibrosis as an experimental marker of efficacy outcomes in myelofibrosis
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, outlines the challenges associated with using fibrosis as a marker of efficacy outcomes in myelofibrosis (MF). Dr Mesa explains that studies have yet to confirm that there is a correlation between improving fibrosis and other important endpoints of response, and thus remains an experimental marker of efficacy outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AOP: Consultancy; Promedior: Research Funding; Genotech: Research Funding; Samus: Consultancy, Research Funding; AbbVie: Research Funding; LaJolla Pharmaceutical: Consultancy; Sierra Oncology: Consultancy, Research Funding; Constellation Pharmaceuticals, Inc., a MorphoSys Company: Consultancy, Research Funding; CTI: Research Funding; Roche: Consultancy; Celgene: Research Funding; Incyte: Consultancy, Research Funding; Blueprint: Consultancy; Bristol Myers Squibb: Consultancy; Novartis: Consultancy; Geron: Consultancy; Gilead: Research Funding; Imago: Research Funding.
